Immunomodulating agent pentoxifylline reduces the inflammatory activity in patient with high-risk non-ST-segment elevation acute coronary syndromes results of the randomized, double-blind, placebo-controlled, reduction of cardiac adverse events acute coronary syndromes with pentoxifylline (RECAP) pilot trial
Juliano L. Fernandes Romulo T Oliveira; Ronei L Mamoni; Jose C Nicolau; Otavio R Coelho; Maria Heloisa S Blotta; Carlos Vicente Serrano Junior; Scientific Sessions of the American Heart Association (2004 New Orlean, Louisiana)
Circulation Philadelphia v. 110, n. 17, supl. 3, p. 449, res. 2113, 2004
Philadelphia 2004
Localização:
FM - Fac. Medicina
(BCSEP 2004 066 ) e outros locais(Acessar)